Literature DB >> 18563946

Pharmaceutical risk-sharing agreements.

Joseph P Cook1, John A Vernon, Richard Manning.   

Abstract

Increased spending on pharmaceuticals continues to foster debate over healthcare policy. The increasing costs of bringing products to the market, as well as increased utilization of pharmaceuticals contribute to increased pharmaceutical expenditure; however, appropriate pharmaceutical use can, in certain cases, reduce overall healthcare costs. Nevertheless, the perception of high drug prices still puts pressure on pharmaceutical companies to build confidence in the proposition that their products are worth the additional expense. One potential approach to building this confidence, and maintaining investment incentives, is for the pharmaceutical company to share the risk of a situation in which there is uncertainty about whether the product is effective for the consumer and payer. Such risk-sharing arrangements for pharmaceuticals, like warranties, can be used to signal high quality when product quality is not fully observable. While there may be difficulties in devising such schemes for every product, such risk-sharing plans may become a staple feature of the market in the future.

Mesh:

Year:  2008        PMID: 18563946     DOI: 10.2165/00019053-200826070-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  6 in total

1.  Explaining drug spending trends: does perception match reality?

Authors:  R W Dubois; A J Chawla; C A Neslusan; M W Smith; S Wade
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

2.  Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.

Authors:  F R Lichtenberg
Journal:  Health Aff (Millwood)       Date:  2001 Sep-Oct       Impact factor: 6.301

3.  Do (more and better) drugs keep people out of hospitals?

Authors:  F R Lichtenberg
Journal:  Am Econ Rev       Date:  1996-05

4.  Warranties as signals under consumer moral hazard.

Authors:  N A Lutz
Journal:  Rand J Econ       Date:  1989

5.  Pharmaceuticals in U.S. health care: determinants of quantity and price.

Authors:  Ernst R Berndt
Journal:  J Econ Perspect       Date:  2002

6.  Do new prescription drugs pay for themselves? The case of second-generation antipsychotics.

Authors:  Mark Duggan
Journal:  J Health Econ       Date:  2005-01       Impact factor: 3.883

  6 in total
  19 in total

1.  Use of economic evaluation in decision making: evidence and recommendations for improvement.

Authors:  Steven Simoens
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

2.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

3.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Pharmaceutical risk-sharing agreements.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  The business case for cell and gene therapies.

Authors:  Mohamed Abou-El-Enein; Gerhard Bauer; Petra Reinke
Journal:  Nat Biotechnol       Date:  2014-12       Impact factor: 54.908

Review 6.  Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.

Authors:  Simon Eckermann; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 7.  Sustainable Financing of Innovative Therapies: A Review of Approaches.

Authors:  Aidan Hollis
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

Review 8.  The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

Authors:  Fernando Antonanzas; Carmelo Juárez-Castelló; Reyes Lorente; Roberto Rodríguez-Ibeas
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

Review 9.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 10.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.